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Abstract We performed a retrospective analysis on kidney
biopsies of 30 human immunodeficiency virus (HIV)-
positive patients. Twenty-two of them received highly
active antiretroviral therapy (HAART). Tenofovir contain-
ing HAART together with atazanavir, a new protease
inhibitor, was administered to three patients. All of them
developed acute renal failure. The kidney biopsies of these
patients showed an acute interstitial nephritis or a chronic
interstitial nephritis with an acute component. Withdrawal
of atazanavir and tenofovir resulted in recovery of renal
function in all three patients. Acute interstitial nephritis was
observed only in 1 of 19 patients without atazanavir or
tenofovir treatment. We conclude that acute interstitial
nephritis and consecutive acute renal failure is a relevant
side effect of atazanavir and tenofovir therapy in HIV-
positive patients.
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Introduction
Renal disease has become increasingly prevalent in human
immunodeficiency virus (HIV)-positive patients [2, 3, 25].
This can be explained by prolonged survival due to
improved treatment, resulting in increased long-term com-
plications from the underlying disease [20, 24]. Kidney
disease can be caused directly through HIV, opportunistic
infections, or drug-related effects [20]. Acute renal failure in
HIV infection overall is rare but may be caused by the toxic
effects of antiretroviral therapy or nephrotoxic antimicrobial
substances used in the treatment of opportunistic infections
[2, 24]. Chronic renal disease can be caused by multiple
pathophysiological mechanisms, leading to HIV-associated
nephropathy (NP), a form of collapsing focal glomerulo-
sclerosis, thrombotic microangiopathy, and various forms
of immune complex glomerulonephritis (GN) [20].
HIV-infected patients frequently develop resistance
patterns of their virus. Therefore, various new antiretroviral
agents were introduced in recent years. Although these
medications are effective, they may have unknown side-
effect profiles that are discovered only during post-
marketing surveillance. Acute renal failure induced by
antiretroviral therapy has been described for zidovudine,
delavirdine (rhabdomyolysis with myoglobinuria), tenofovir,
ritonavir (direct tubular toxicity), and indinavir (crystal
NP, acute interstitial nephritis) [20, 23, 24]. Atazanavir is a
new protease inhibitor that shows a high specificity for
HIV-1 protease. This protease inhibitor was released in
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2004 [1, 20]. So far, two cases of acute interstitial nephritis
under atazanavir therapy have been published in the
literature [1, 17]. Consequently, we investigated the fre-
quency of kidney pathology, especially the occurrence of
acute interstitial nephritis in kidney biopsies of 30 HIV-
positive patients, with special emphasis on atazanavir
therapy.
Materials and methods
Patients
The reports of all kidney biopsies in the archives of the
Institute of Surgical Pathology, University Hospital Zurich,
between 1990 and 2006 were screened for HIV-infected
patients (see also “Discussion”). The information on HIV
infection came from the clinicians. There were kidney
biopsies of 30 HIV-positive patients, 15 of which were
performed because of renal function impairment (Table 1).
Histological slides and ultrastructural findings were reeval-
uated in each patient (S.S, Z.V). There were 21 male and 9
female patients with an age of 23 to 63 years (median
35 years). Three patients were of African origin. Twenty-
two patients received highly active antiretroviral therapy
(HAART). Four patients received tenofovir-containing
HAART, three of them together with atazanavir. Three
other patients received indinavir-containing HAART.
Clinical data are summarized in Tables 1, 3, and 4.
Histology and light microscopy
Tissue specimens had been routinely fixed in 4% formalde-
hyde and embedded in paraffin. Sections were cut (2 μm
thick) and attached to polylysine-coated glass slides. Routine
hematoxylin and eosin stains were performed as well as
special staining procedures: periodic acid-Schiff (PAS), acid
fuchsin-Orange G (SFOG), Elastin–van Gieson (EVG), and
silver on all slides. Renal diseases were diagnosed according
to criteria by textbooks [4, 6, 13, 15, 22]. The diagnosis of
acute interstitial nephritis required interstitial edema, in-
creased lymphocytes, and tubulitis. Eosinophilic granulo-
cytes were present in two of three cases.
Immunofluorescence/immunohistochemistry
In all cases, stains for IgA (1:30 dilution, Dako, Glostrup,
Denmark), IgG (1:25 dilution, Dako), IgM (1:40 dilution,
Dako), and C3 (1:80 dilution, Dako) and, in some cases,
also for C1q (1:20 dilution, Dako), kappa (1:20 dilution,
Dako), and lambda (1:30 dilution, Dako) were performed
on frozen sections by using the standardized Ventana
Benchmark system (Ventana Medical Systems, Tucson,
AZ). The reaction products were visualized with the iVIEW
DAB detection kit on the Ventana Benchmark system
according to the manufacturer’s recommendations. If no
fresh tissue was available, immunohistochemical reactions
for IgA, IgG, IgM, and C3 were carried out on paraffin
sections via the same procedure.
Following markers were tested immunohistochemically
on paraffin sections on the cases with acute interstitial
nephritis: T cell and B cell markers: CD4 (1:10 dilution,
Novocastra, Newcastle, UK), CD8 (1:100 dilution, Dako),
CD20 (1:400 dilution, Dako); Granzyme B (1:25 dilution,
Dako), Fas (1:20 dilution, Novocastra), TIA-1 (1:400
dilution, Immunotech S.A., Marseille, France), FoxP3
(1:50 dilution, Abcam, Cambridge, UK).
Electron microscopy
Specimens were processed according to standard proce-
dures as follows: The kidney biopsy was fixed in
phosphate-buffered 2.5% glutaraldehyde and 2% osmium
tetroxide, dehydrated in alcohol and propylene oxide, and
embedded in Epon. Ultrathin sections were cut, contrasted
Table 1 Summary of clinical data
Values
Age 23–63
Gender
Male/female 21/9
Antiviral therapy 22/30
Atazanavir 3
Tenofovir 4
Ritonavir 8
Lopinavir 6
Lamivudine 11
Emtricitabine 1
Didanosine 3
Zidovudine 7
Efavirenz 2
Abacavir 4
Indinavir 3
Nelfinavir 2
Stavudine 2
Foscarnet 1
Clinical symptoms
Proteinuria 21
Hematuria 13
Renal insufficiency 15
Acute renal failure 5
Nephrotic syndrome 3
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with uranyl acetate and lead citrate, and examined by
transmission electron microscope.
Results
A variety of histopathological lesions were diagnosed in the
30 kidney biopsies (Table 2).
Immune complex GN was the most common histological
finding, identified in 13 patients: 4 membranous GN, 3
membranoproliferative GN (1 type 1 and 2 type 3), 2 IgA
NP, 1 postinfectious GN, 1 immunotactoid GN, 1 anti-
GBM-GN, 1 immune complex GN not otherwise specified.
Two of three patients with membranoproliferative GN were
coinfected with hepatitis C virus, and one had visceral
leishmaniosis.
Interstitial nephritis was diagnosed in six patients. Five
patients were treated with antiretroviral therapy, the
combination of atazanavir and tenofovir was taken by three
of them. These latter three patients all showed acute
interstitial nephritis (Fig. 1), two of them also signs of
chronicity (interstitial fibrosis and tubular atrophy). With-
drawal of atazanavir and tenofovir resulted in recovery of
renal function in all three patients.
Only in one of these three patients, there was a focal
acute tubular necrosis as a minor component, which is the
typical described manifestation of tenofovir on the kidney.
One additional patient, who was administered foscarnet
without anti-HIV therapy, also exhibited acute interstitial
nephritis. Chronic interstitial nephritis was observed in two
patients (one patient had received no antiretroviral therapy,
the other patient had been treated with zidovudine,
lamivudine, indinavir). The majority of the infiltrating
interstitial lymphocytes were CD8 positive T cells, to lesser
extent CD4 positive T cells were also present. There were a
few CD20 positive B cells mixed within the T cell
population. Lymphocytes in all cases showed focal positiv-
ity for Granzyme B, TIA-1, and FoxP3. Stains for Fas were
not conclusive.
Details of patients’ medication with acute interstitial
nephritis are summarized in Tables 3 and 4.
Acute tubular necrosis was seen in five patients. Only
one patient showed acute tubular necrosis without other
findings during treatment with tenofovir, didanosine,
lopinavir, ritonavir, esomeprazole, paracetamol. This pa-
tient had additionally received a contrast medium 1 month
earlier. Acute tubular necrosis was observed as an epiphe-
nomenon in the other four patients accompanying IgA NP,
membranous GN, or interstitial nephritis.
Focal segmental glomerulosclerosis (FSGS) was ob-
served in five patients. Two of these patients had a
collapsing variant of FSGS (classical HIV-associated NP),
both patients were of African origin.
Thrombotic microangiopathy was seen in four patients.
Two biopsies with mainly vascular changes included one
diabetic NP and one hypertensive NP. Renal changes
caused by opportunistic infections were not observed in
any of the cases in our series.
Tubuloreticular aggregates, which can be found in
glomerular endothelium cells of HIV-positive patients and
patients with systemic lupus, were detected by ultrastruc-
tural examination in 13 patients. They were less frequent in
patients treated with HAART (30%) than in patients
without antiretroviral therapy (75%).
Discussion
In this study, we identified three patients who presented
with acute renal failure and acute interstitial nephritis in the
Table 2 Summary of renal changes
Diagnosis Number of patients (n)
Immune complex glomerulonephritis 13
Interstitial nephritis 6
Acute tubular necrosis 5
Thrombotic microangiopathy 4
Focal segmental glomerulosclerosis 5
Vascular changes 2
Pyelonephritis 1
HIV-associated nephropathy 2
Indinavir crystal nephropathy 1
Amyloidosis 1
Fig. 1 Acute interstitial nephritis. The renal tubuli are separated
through interstitial edema and increased inflammatory cells, as
lymphocytes and plasma cells (asterisk) as well as eosinophilic
granulocytes (arrows). HE, ×200
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biopsy while receiving atazanavir and tenofovir containing
HAART. These were the only three patients who presented
with acute interstitial nephritis while receiving an antire-
troviral therapy.
Improved survival of patients with HIV infection was
reached with antiretroviral therapy, but may result in side
effects of medication, especially in HAART-associated
complications [20, 24]. Since the introduction of HAART,
a wide range of renal side effects and adverse drug
reactions have been recognized, varying from proteinuria
to acute renal failure [20, 23, 24]. Not much data are
available on side effects and kidney pathology arising under
atazanavir therapy [20]. Only two patients with acute
interstitial nephritis have been reported in the literature so
far, one of them is a patient in our study [1, 17]. According
to our knowledge, no systematic clinicopathological case
series has analyzed the incidence of acute interstitial
nephritis under atazanavir therapy up to now.
In our series, the three cases of acute interstitial nephritis
during HAART occurred during concomitant therapy with
atazanavir and tenofovir, and the kidney function normal-
ized after both atazanavir and tenofovir were stopped.
Based on treatment history, we cannot attribute this
phenomenon to one of the drugs alone. In all three patients,
the acute interstitial nephritis occurred between 6 and
16 weeks after starting ritonavir-boosted atazanavir. Two
of these patients had initiated tenofovir together with
atazanavir, while the third patient had been receiving
tenofovir already for 17 months without previous increase
in serum creatinine. This time course, thus, favors atazanavir
to be the causative agent, which is also supported by the
histological picture of interstitial nephritis without tubular
Table 3 Patients with acute renal failure and acute interstitial nephritis
Patients Diagnosis Drugs
51-year-
old man
Acute interstitial nephritis Atazanavir, tenofovir, ritonavir, lamivudine (all since 3 months); amoxicillin/
clavulanic acid, oxazepane, methadone, esomeprazole
44-year-
old woman
Chronic interstitial nephritis with acute
component
Atazanavir, tenofovir, ritonavir, emtricitabine (all since 6 weeks)
63-year-
old man
Chronic interstitial nephritis with acute
component and focal tubular necrosis
Atazanavir (since 4 months), lopinavir/ritonavir (since 4.5 years), tenofovir (since
17 months), lamivudine (since 4 years), didanosine (since 4 months), acidum
salicylicum, clopidogrelum, calcium acetate, spironolactone, metoprololi succinas,
epoetinum beta, insuline, atorvastatine, rosiglitazone
31-year-
old man
Acute to subacute interstitial nephritis with
focal acute tubular necrosis
Foscarnet, aluminii oxidum hydricum/magnesii hydroxidum, ranitidine, calcium
acetate, sucralfate
Table 4 Clinical data and time course of three patients with acute interstitial nephritis under atazanavir and tenofovir
51-year-old man 44-year-old woman 63-year-old man
CDC stage C2 C3 A3
Actual CD4 (count/μl) 269 160 415
Duration anti-HIV therapy 13 months 6 weeks 9.5 years
Duration atazanavir 3 months 6 weeks 4 months
Duration tenofovir 3 months 6 weeks 17 months
Other illnesses Alcohol abuse,
emphysema
i.v. drug use Diabetes mellitus, coronary
heart disease
Serum creatinine before start of atazanavir
(μmol/l)
Normal 68 96
Peak serum creatinine (μmol/l) 913 302 622
Calculated GFR (ml/min, Cockcroft) 8 14 11
Urine protein (g/l) 0.75 0.5 1.0
Other abnormal urine results Erythrocytes ↑ Leucocytes ↑, erythrocytes (↑) Glucose ↑
Urine eosinouria nd nd nd
Blood eosinophils (/μl) 200 50 240
Subsequent HAART with normalization of
serum creatinine
Nevirapine, abacavir,
lamivudine
Lopinavir/ritonavir, zidovudine,
lamivudine
Lamivudine (monotherapy)
Histology and complete list of medication is given in Table 3
nd Not done
668 Virchows Arch (2007) 450:665–670
necrosis. Although there are several reports of renal
insufficiency associated with tenofovir, the overall occur-
rence is rare, and only few of these patients had kidney
biopsies [14, 19, 21]. The typical picture of tenofovir NP
was extensive acute tubular necrosis [14, 19, 20]. There are
no published reports of acute interstitial nephritis due to
tenofovir; however, the European Medicines Agency
recently included acute interstitial nephritis as one of the
possible adverse reactions to tenofovir [5].
We cannot exclude a potential additive effect of atazanavir
and tenofovir on the development of NP. In addition,
atazanavir and tenofovir given together display significant
interactions, with lowering of atazanavir and increasing of
tenofovir plasma levels [18]. Ritonavir also increases the
plasma concentrations of tenofovir. Interestingly, the com-
bination of tenofovir with protease inhibitors seems to
impair the kidney function at a higher magnitude than
tenofovir with non-nucleoside reverse transcriptase [8, 9].
In the Zurich site of the Swiss HIV Cohort Study, which
covers the majority of patients whose kidney biopsies
would be sent to our hospital, 670 patients have received
atazanavir, and 1,230 received tenofovir since their first use
in 2000. Because not all treated patients in our area
participate in the Swiss HIV Cohort Study, we estimate
the risk of acute interstitial nephritis to be less than 0.57%
(3 of 524 patients) among those who received both
atazanavir and tenofovir within the framework of the
Cohort Study in the last 6 years.
Atazanavir was registered in 2004. It is known to bear a
favorable side-effect profile with significantly fewer lipid
changes as compared to other protease inhibitors [7, 12, 16,
20]. The underlying mechanism of acute interstitial nephri-
tis caused by atazanavir is not clear. Brewster and Perazella
[1] speculate on a hypersensitivity reaction as a possible
explanation for this phenomenon. The presence of eosino-
philic granulocytes in two of our three cases would support
this theory. We demonstrated a prevailing subset of CD8
positive T cells and some CD4 positive T cells in the
interstitial lymphocytes, which supports a potential role of
cell mediated mechanisms in the pathogenesis of tubuloin-
terstitial nephritis in our patients [13]. A granulomatous
reaction, usually occurring in delayed type hypersensitivity
reactions caused by CD4 positive lymphocytes, could not
be detected in our series. A cytotoxic T cell injury, mediated
by CD4 and CD8 positive T cells, does not require prior
sensitization, which is therefore a potential underlying
mechanism of the tubulointerstitial injury [13]. The
presence of activated cytotoxic T cells in our patients may
point to this pathomechanism.
Acute renal failure as a side effect of antiretroviral
therapy has been described in the literature [20, 23, 24].
Rhabdomyolysis with myoglobinuria was reported under
zidovudine and delavirdine therapy [20, 23, 24]. Indinavir-
induced crystal NP and acute tubular damage due to
tenofovir and ritonavir are well-known side effects of drugs
used for HIV treatment [20, 23, 24]. Tenofovir was
administered together with atazanavir in all three patients;
nevertheless, an extensive acute tubular necrosis, as a
known side effect of tenofovir therapy, did not occur; we
could demonstrate only a focal acute tubular necrosis in one
of these patients.
Tubulointerstitial injuries, as inflammation, fibrosis, or
tubular atrophy, are common features in interstitial ne-
phropathies. If the underlying tubular or interstitial damage
cannot be eliminated, these changes can give rise to chronic
interstitial nephritis [13]. Furthermore, acute and chronic
changes in the same tubulointerstitial compartment can
coexist if etiologic factors become repeatedly manifest [13].
The frequency of interstitial nephritis in HIV infection
varies in the literature. Diversity in its occurrence is mainly
due to patient selection after and before antiretroviral
therapies [10, 22]. In a recent study of Han et al. [11],
615 HIV-positive patients, all of them without antiretroviral
therapy, were screened for proteinuria. Thirty patients were
selected and underwent renal biopsy. Interstitial nephritis
was only seen in 3 of 30 patients (10%). In an earlier
autopsy study, Hailemariam et al. [10] determined the
percentage of interstitial nephritis in Swiss HIV-positive
patients, not treated with HAART, and reported a low
prevalence with 14 of 239 patients (5.9%). However, of
these 239 patients, 64% did not show clinical signs of NP
before death. Therefore, the prevalence of interstitial
nephritis might be higher in the group with clinical signs
of NP.
Our study includes a time span after the introduction of
HAART therapy. This might explain the higher prevalence
of interstitial nephritis as compared to Han et al. and
Hailemariam et al. [10].
The real frequency of interstitial nephritis arising under
atazanavir and tenofovir therapy is, however, unclear. One
reason is the patient selection. Not all patients receiving
atazanavir and tenofovir will undergo kidney biopsy during
the disease course. Subclinical or clinical acute interstitial
nephritis, therefore, cannot be diagnosed and could be well
missed in a subset of patients receiving this medication.
Prospective studies with clearly defined patient collectives
and protocol kidney biopsies will be necessary to address
the incidence of acute interstitial nephritis under atazanavir
and tenofovir therapy.
Interestingly, our study confirms that HIV-associated NP,
a collapsing variant and secondary form of FSGS, is
predominantly a disease of black patients, because we have
observed this NP only in the black patients of our group. A
variety of other glomerular diseases have been described in
HIV-infected patients, as thrombotic microangiopathy and
various forms of immune complex GN. According to the
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literature [3, 4, 22], one of the most common immune
complex-mediated glomerular lesion is membranoprolifer-
ative GN, particularly in HIV-infected patients coinfected
with hepatitis C virus. These patients develop membrano-
proliferative GN type 1 or type 3 (with mixed membranous
features). IgA NP, membranous GN, lupus-like GN, and
immunotactoid GN are other immune complex-mediated
glomerular lesions found in HIV-positive patients. The
glomerular changes seen in our series correlate well with
these data in the literature. Membranoproliferative GN,
membranous GN, and IgA NP were the most commonly
diagnosed immune complex-mediated glomerular diseases.
In addition, in our study, membranoproliferative GN was
particularly observed in HIV-infected patients coinfected
with hepatitis C virus. It consisted of type 1 and type 3
membranoproliferative GN. Besides immune complex GN,
thrombotic microangiopathy was a frequent lesion.
In summary, our findings show that acute interstitial
nephritis can occur under atazanavir and tenofovir therapy.
This side effect of antiretroviral medication should be
considered in treatment planning for HIV-positive patients.
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